| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
L-type calcium channel
Cycleanine targets calcium channels as a potent vasculoselective Ca-antagonist. The compound also exerts its effects through the apoptotic pathway, making it a potential anti-ovarian cancer agent. Cycleanine has antibacterial, antifungal, antiplasmodial, and cytotoxic activities. The compound's diverse pharmacological effects include pain-relieving, muscle-relaxing, and anti-inflammatory activities. |
|---|---|
| ln Vitro |
In a voltage- and frequency-dependent way, cycleanine suppresses the L-type Ca-current (ICaL) of single rat ventricular cardiomyocytes[1]. Cycleanine is slightly less effective than cancer cells against normal human OSE cells[2]. For Ovcar-8, A2780, Igrov-1, and Ovcar-4 cell lines, (20 μM; 48 hours) demonstrates cytotoxicity with IC50s ranging from 7 to 14 μM[2]. Significant PARP cleavage, a hallmark of apoptosis, is caused by cycleanine (20 μM; 24 hours)[2]. Cycleanine (20 μM; 48 hours) significantly increases the population of cells that undergo early and late apoptosis[2]. Cytotoxicity Assay for Cycleanine Cells [2] Cell line: Igrov-1, A2780, Ovcar-8, and Ovcar-4 cells. Focus: 20 micrograms 48-hour incubation period Result shown cytotoxicity against Ovcar-8, A2780, Igrov-1, and Ovcar-4 cell lines, with IC50 values of 10 μM, 7.6 μM, 14 μM, and 7.2 μM, in that order.
In vitro studies demonstrate that cycleanine selectively inhibits the growth of OVCAR-8, A2780, and IGROV-1 cancer cell lines. The compound has potent antibacterial, antifungal, antiplasmodial, and cytotoxic activities. Cycleanine is a potent vasculoselective Ca-antagonist with pain-relieving, muscle-relaxing, and anti-inflammatory activities. The compound may be used to exert anti-ovarian cancer effects through the apoptotic pathway. |
| ln Vivo |
At an IC50 of 0.8 nM, cycleanine prevents rabbit aortic ring contraction caused by KCl[1].
No detailed in vivo activity data has been published for cycleanine as a therapeutic agent. The compound has been primarily characterized in vitro as an alkaloid with anticancer and antimalarial activities. Its ability to selectively inhibit cancer cell growth and its antiplasmodial activity suggest that it could have potential for in vivo applications in cancer and malaria. Further studies would be needed to evaluate its efficacy in animal models. |
| Enzyme Assay |
The calcium channel antagonistic activity of cycleanine can be assessed using electrophysiology or calcium flux assays. In a typical assay, cells expressing calcium channels are treated with varying concentrations of cycleanine, and calcium influx is measured using fluorescent calcium indicators. The compound's ability to inhibit calcium channel activity is assessed. The apoptotic activity of cycleanine can be assessed using cell-based apoptosis assays.
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: Ovcar-8 cells Tested Concentrations: 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induced 1.1-fold increase in PARP-1 cleavage compared with carboplatin. Apoptosis Analysis[2] Cell Types: Ovcar-8 cells Tested Concentrations: 20 μM Incubation Duration: 48 hrs (hours) Experimental Results: Caused a significant increase of the population of both early and late apoptotic cells. Cell Cycle Analysis[2] Cell Types: Ovcar-8 cells Tested Concentrations: 20 μM Incubation Duration: 48 hrs (hours) Experimental Results: Increased the percentage of Ovcar-8 cells in subG1. The cellular activity of cycleanine is assessed using cancer cell lines including OVCAR-8, A2780, and IGROV-1 cells. Cells are seeded in 96-well plates and treated with escalating concentrations of cycleanine. Cell viability is measured using MTT or CellTiter-Glo assays. Apoptosis is assessed by annexin V/propidium iodide staining or caspase activation assays. The compound's antibacterial, antifungal, and antiplasmodial activities can be assessed using appropriate microbial or parasite cultures. |
| Animal Protocol |
No detailed in vivo animal model data has been published for cycleanine as a therapeutic agent. Future studies may involve the use of mouse xenograft models of ovarian cancer to assess the in vivo efficacy of cycleanine. The compound's antiplasmodial activity could be assessed in mouse models of malaria.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data has been published for cycleanine. The compound has a molecular weight of 622.75 and a molecular formula of C38H42N2O6. It appears as a white crystalline powder and is soluble in methanol, ethanol, and DMSO. Further studies would be needed to characterize its absorption, distribution, metabolism, and excretion properties, including oral bioavailability, plasma protein binding, clearance, and half-life.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data has been published for cycleanine. As an alkaloid with diverse pharmacological activities, the compound may have on-target and off-target effects in normal tissues. Comprehensive toxicology studies would be required to evaluate its safety profile for potential therapeutic development. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
Cycleanine alkaloids belong to the isoquinoline class of compounds and are dibenzylisoquinoline alkaloids. They have been reported to exist in Symplocos buergeriana, Cyclohexane tonkinensis, and other organisms with relevant data.
Cycleanine (CAS# 518-94-5) is an alkaloid found in T. subcordata and other plant sources, with anticancer and antimalarial activities. It is a potent vasculoselective Ca-antagonist with pain-relieving, muscle-relaxing, and anti-inflammatory activities. Cycleanine selectively inhibits the growth of OVCAR-8, A2780, and IGROV-1 cancer cells. The compound may be used to exert anti-ovarian cancer effects through the apoptotic pathway. The molecular formula is C38H42N2O6 and molecular weight is 622.75. |
| Molecular Formula |
C38H42N2O6
|
|---|---|
| Molecular Weight |
622.75
|
| Exact Mass |
622.304
|
| CAS # |
518-94-5
|
| PubChem CID |
121313
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
691.6±55.0 °C at 760 mmHg
|
| Flash Point |
169.8±28.7 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.586
|
| LogP |
3.96
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
46
|
| Complexity |
895
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CN1CCC2=CC(=C(C3=C2[C@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC=C(O3)C=C7)N(CCC6=CC(=C5OC)OC)C)OC)OC
|
| InChi Key |
ANOXEUSGZWSCQL-LOYHVIPDSA-N
|
| InChi Code |
InChI=1S/C38H42N2O6/c1-39-17-15-25-21-31(41-3)35(43-5)37-33(25)29(39)19-23-7-11-28(12-8-23)46-38-34-26(22-32(42-4)36(38)44-6)16-18-40(2)30(34)20-24-9-13-27(45-37)14-10-24/h7-14,21-22,29-30H,15-20H2,1-6H3/t29-,30-/m1/s1
|
| Chemical Name |
(11R,26R)-4,5,19,20-tetramethoxy-10,25-dimethyl-2,17-dioxa-10,25-diazaheptacyclo[26.2.2.213,16.13,7.118,22.011,36.026,33]hexatriaconta-1(31),3(36),4,6,13,15,18(33),19,21,28(32),29,34-dodecaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 5 mg/mL (8.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6058 mL | 8.0289 mL | 16.0578 mL | |
| 5 mM | 0.3212 mL | 1.6058 mL | 3.2116 mL | |
| 10 mM | 0.1606 mL | 0.8029 mL | 1.6058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
